This study examined how much money Germany should invest in developing a new ME/CFS drug to provide the greatest benefit to patients and society. Researchers calculated that an effective ME/CFS drug could improve quality of life for thousands of patients and save billions of euros, and they determined that Germany's optimal investment would be around €676 million. The study emphasizes that developing ME/CFS treatments requires countries to work together internationally because no single country can bear the full cost alone.
Why It Matters
This study provides concrete economic justification for substantial public investment in ME/CFS drug development, demonstrating significant potential returns to society through improved patient outcomes and reduced economic burden. By quantifying both the human and financial impact, it strengthens the case for prioritizing ME/CFS research funding at national and international levels, addressing a historically underfunded disease area.
Observed Findings
A prospective ME/CFS drug is projected to generate approximately 29,000 quality-adjusted life years in Germany.
Total estimated societal value of an effective ME/CFS drug is approximately €2.6 billion from the German perspective.
Optimal R&D investment for Germany is estimated at €676 million, representing about 25% of total drug development costs.
Sensitivity analyses confirmed the robustness of the investment recommendation across different scenarios.
Inferred Conclusions
Public investment in ME/CFS drug development represents economically justified allocation of healthcare resources with substantial societal returns.
International coordination among multiple countries is essential to distribute R&D costs and achieve the market scale necessary for successful drug development.
Germany's proportional contribution to global ME/CFS drug development efforts should be approximately €676 million to optimize societal benefit.
Remaining Questions
Which specific drug candidates or therapeutic approaches should be prioritized to achieve the modeled efficacy assumptions?
How should international R&D funding be coordinated across countries, and what mechanisms would ensure equitable cost-sharing and access?
What This Study Does Not Prove
This study does not prove that a prospective drug with the assumed efficacy actually exists or will be successfully developed—it is a theoretical economic model. It does not establish which specific drug candidates are most promising, nor does it guarantee that the calculated investment level will actually result in a viable treatment. The analysis depends on assumptions about drug effectiveness that would require clinical trial validation to confirm.